---
title: "ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.41"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252920371.md"
datetime: "2025-08-13T21:04:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252920371.md)
  - [en](https://longbridge.com/en/news/252920371.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252920371.md)
generator: "portal-rs"
---

# ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.41

EPS: As of FY2025 Q2, the actual value is USD -0.41.

EBIT: As of FY2025 Q2, the actual value is USD -17.92 M.

### Segment Revenue

-   No revenue has been earned as of June 30, 2025.

### Operational Metrics

-   **Net Loss**: For the three months ended June 30, 2025, net loss was - $1,981,293 compared to - $96,923 for the same period in 2024, reflecting an increase of - $1,884,370.
-   **General and Administrative Expenses**: Increased to $395,692 for the three months ended June 30, 2025, from $86,423 for the same period in 2024, reflecting an increase of $309,269.
-   **Research and Development Expenses**: Increased to $352,887 for the three months ended June 30, 2025, from $10,500 for the same period in 2024, reflecting an increase of $342,387.
-   **Sales and Marketing Expenses**: Increased to $51,311 for the three months ended June 30, 2025, from $0 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $2,891,838 for the six months ended June 30, 2025, compared to - $249,215 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $3,094,438 for the six months ended June 30, 2025, compared to $257,645 for the same period in 2024.

### Unique Metrics

-   **Convertible Notes**: The fair value of convertible notes at June 30, 2025, was $3,617,508.

### Future Outlook and Strategy

-   **Core Business Focus**: Aspire plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company expects to commence commercialization activities by building a focused sales and marketing organization in the United States to sell its products, subject to receiving marketing approvals.
-   **Non-Core Business**: Aspire is exploring licensing possibilities for its sublingual melatonin sleep-aid product and has developed formulations for sublingually administered vitamins and testosterone, with plans for clinical testing and NDA submissions.

### Priority

-   Aspire plans to seek FDA 505(b)(2) Fast Track designation for its prescription strength high dose aspirin product in 2025.

### Related Stocks

- [ASBPW.US](https://longbridge.com/en/quote/ASBPW.US.md)

## Related News & Research

- [Balanced Risk/Reward Keeps Workday at Hold as Brent Thill Raises Price Target from $205 to $225 on Potential Silver Lake Takeout Upside](https://longbridge.com/en/news/296711228.md)
- [3,759 Shares in Ferrari N.V. $RACE Acquired by X Square Capital LLC](https://longbridge.com/en/news/296700358.md)
- [Korea Investment CORP Increases Stock Position in L3Harris Technologies Inc $LHX](https://longbridge.com/en/news/296698330.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Danske Bank A S Invests $252.05 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296695181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**